Home
Issues
Aim & Scope
Open Access
Editorial Board
Indexing
Supporting Midwifery Associations
Contact us
Manuscript Types
Manuscript Formatting
How to submit
Special publications and Reprints
Authorship & COI
Principles of Transparency Checklist
Publication Ethics and Publication Malpractice Statement
CONFERENCE PROCEEDING
The RSVoyage vaccine in pregnancy, a collaboration of clinical research teams, aiming to prevent RSV infections in babies by vaccinating their mothers
1
Cardiff and Vale NHS Trust- University Hospital of Wales- Cardiff CF14 4XW, Obstetrics and Gynaecology, Cardiff, United Kingdom
Eur J Midwifery 2026;10(Supplement 1):A55
ABSTRACT
PURPOSE:
Here at Cardiff and Vale NHS Trust we were fortunate to be involved and successfully recruit a participant for the RSVoyage vaccine in pregnancy. The trial was a Phase 2, randomized, observer-blind, placebo-controlled, dose-escalation study to evaluate the reactogenicity, safety, and immunogenicity of mRNA-1345, an mRNA vaccine targeting respiratory syncytial virus, in pregnant women, and safety and immunogenicity in infants born to vaccinated mothers. The vaccine aimed to assess whether an investigational vaccine, mRNA-1345, given to pregnant mothers could offer immunity to their babies from respiratory syncytial virus (RSV) infection.
DISCUSSION:
RSV is a common cause of lower respiratory tract infections in children, especially infants under 6 months old. RSV can lead to serious respiratory tract problems, especially in young children. RSV annually is associated with over 100,000 deaths of children across the world and is the most common cause of young children being admitted to hospital. The significance and impact to patients of the infection is what allowed us a team to drive through and successfully recruit a participant.
EVIDENCE WHERE RELEVANT:
The significance and impact to patients of the infection is what allowed us a team to drive through and successfully recruit a participant, the only participant in Wales.
KEY MESSAGE:
The significance and impact to patients of the infection is what allowed us a team to drive through and successfully recruit a participant. The window for recruitment was limited with difficult recruitment, due to the sensitivity of the patient group and the rollout of the NHS RSV vaccine. Not only was the study a collaboration with Moderna worldwide but the study allowed for collaborative working across individual teams within our CRF (maternity, vaccine, paediatrics and laboratory teams), which was incredible to be part of allowing research to flourish across all teams involved allowing for greater patient care, satisfaction and enhanced working relationships. Complications - other
Here at Cardiff and Vale NHS Trust we were fortunate to be involved and successfully recruit a participant for the RSVoyage vaccine in pregnancy. The trial was a Phase 2, randomized, observer-blind, placebo-controlled, dose-escalation study to evaluate the reactogenicity, safety, and immunogenicity of mRNA-1345, an mRNA vaccine targeting respiratory syncytial virus, in pregnant women, and safety and immunogenicity in infants born to vaccinated mothers. The vaccine aimed to assess whether an investigational vaccine, mRNA-1345, given to pregnant mothers could offer immunity to their babies from respiratory syncytial virus (RSV) infection.
DISCUSSION:
RSV is a common cause of lower respiratory tract infections in children, especially infants under 6 months old. RSV can lead to serious respiratory tract problems, especially in young children. RSV annually is associated with over 100,000 deaths of children across the world and is the most common cause of young children being admitted to hospital. The significance and impact to patients of the infection is what allowed us a team to drive through and successfully recruit a participant.
EVIDENCE WHERE RELEVANT:
The significance and impact to patients of the infection is what allowed us a team to drive through and successfully recruit a participant, the only participant in Wales.
KEY MESSAGE:
The significance and impact to patients of the infection is what allowed us a team to drive through and successfully recruit a participant. The window for recruitment was limited with difficult recruitment, due to the sensitivity of the patient group and the rollout of the NHS RSV vaccine. Not only was the study a collaboration with Moderna worldwide but the study allowed for collaborative working across individual teams within our CRF (maternity, vaccine, paediatrics and laboratory teams), which was incredible to be part of allowing research to flourish across all teams involved allowing for greater patient care, satisfaction and enhanced working relationships. Complications - other
| eISSN: | 2585-2906 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
